Appointment dossier — Bladder Cancer
Bring this to your appointment. It summarizes what published studies report — it is not medical advice and does not say anything works. Decisions are yours and your care team’s.
Compounds studied in Bladder Cancer
- Genistein — Review evidence · 1 positive · PMID 42133114
“Positive” means a study reported a positive result — most are early lab/animal work that may not translate to people.
Open recruiting trials (18)
- NCT07129993 · Phase 2 / Phase 3 — Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma (United States)
- NCT06696794 · Phase 3 — Investigating the Efficacy and Safety of Neoadjuvant Intravesical Instillation of Mitomycin C in Treating High-risk NMIBC Patients (China)
- NCT06703476 · Phase 3 — A Study of Surgical Techniques During Cystectomy (United States)
- NCT06851663 · Phase 2 / Phase 3 — Trop2-targeted immunoPET Imaging of Solid Tumors (China)
- NCT07067749 · Phase 3 — Treatment Expedition With MRI Processing and Optimization for Muscle Invasive Bladder Cancer (Italy)
- NCT07025174 · Phase 2 — Sequential Anti-Angiogenic Therapy After Immunotherapy in Advanced Biliary Tract Cancer (China)
- NCT05086692 · Phase 1 / Phase 2 — A Beta-only IL-2 ImmunoTherapY Study (United States)
- NCT07475403 · Phase 2 — Urinary Tumor DNA-Guided Systemic Immunotherapy for Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer (China)
- NCT07468851 · Phase 1 / Phase 2 — A Study of HS-10566 in Patients With High-risk Non-muscle-invasive Bladder Cancer Who Are Ineligible for or Refuse Radical Cystectomy (China)
- NCT06916494 · Phase 1 — Pilot Study on Rutin Combined With Tislelizumab and GC (Gemcitabine and Cisplatin) as Neoadjuvant Therapy for Platinum-refractory Muscle-invasive Bladder Cancer (China)
- NCT05453682 — Hypofractionated IMRT With Concurrent Chemotherapy in Muscle-invasive Bladder Cancer (HIRACUM) (South Korea)
- NCT07339761 — Supporting Sexual Health in Bladder Cancer Patients: A Sequential Mixed-Methods Intervention Study (Denmark)
- NCT07782164 — Irreversible Electroporation (IRE) for Treating Recurrent Pelvic Tumors (PELFIRE Study) (Netherlands)
- NCT04235764 — En-bloc Transurethral Resection of Bladder Tumor (En-bloc TURBT) Specimens Using a Redesigned Surgical Resectoscope Device (United States)
- NCT07395037 — A Study of Ward Admissions for Haematuria (United Kingdom)
- NCT06092450 — Deep Learning Radiomics Model for Predicting Post-cystectomy Outcome in Muscle Invasive Bladder Cancer (China)
- NCT07111364 — Construction of a Deep Learning-Based Precise Diagnostic Framework for Bladder Tumors Using Ultrasound: A Multicenter, Ambispective Cohort Study (China)
- NCT06170177 — Study on the Quality of Life and Pathological State in Patients Who Underwent Radical Cystectomy (Italy)
Most-relevant first: trials that name Bladder Cancer, then broader trials you may still qualify for. 402 recruiting trials name this cancer on ClinicalTrials.gov. Eligibility is decided by each trial's team — bring these NCT numbers to your appointment.
Financial help to look into
- PAN Foundation — Copay assistance funds by diagnosis (funds open and close as money allows). https://www.panfoundation.org/
- HealthWell Foundation — Copay and premium assistance funds by disease. https://www.healthwellfoundation.org/
- CancerCare — financial assistance — Limited grants plus free financial counseling. https://www.cancercare.org/financial
- Family Reach — Help with everyday living costs (rent, transport, food) during treatment. https://familyreach.org/
- NeedyMeds — Searchable directory of drug patient-assistance and discount programs. https://www.needymeds.org/
For each medicine above, search manufacturer and nonprofit programs at medicineassistancetool.org.
Questions to ask your oncologist
- Of the open trials I found (for example NCT07129993), am I eligible for any — here or at a larger cancer center?
- What is my exact diagnosis — the type, subtype, stage, and grade?
- Has my tumor had molecular or genomic testing (e.g. next-generation sequencing), and what did it find?
- Should I have inherited (germline) genetic testing, and could it affect my treatment or my family?
- What is the goal of treatment for me — cure, long-term control, or comfort?
- What are all of my standard treatment options, and what does each one involve?
- What is the realistic benefit of each option, in actual numbers?
- What are the most common and the most serious side effects, and how are they managed?
- How will we know if treatment is working, and how often will I be scanned or tested?
- If the first treatment doesn't work, what are the next options?
- Are there gentler options if I want to prioritize quality of life?
- Am I eligible for any clinical trials — here or at a larger/academic cancer center?
- Is my case reviewed by a multidisciplinary tumor board?
- Would a second opinion at a center that treats my cancer often be worthwhile?
- Could any of my prescriptions, over-the-counter drugs, or supplements interfere with treatment?
- Which symptoms are emergencies, and who do I call after hours?
- Should I see palliative or supportive care alongside my treatment?
- How will treatment affect my daily life, work, and (if it matters to me) fertility?
- What can I safely do myself — diet and activity — and is anything I'm taking risky?
- What will treatment cost, and is financial assistance available?
- Should my tumor tissue be stored (biobanked) for future testing or trials?